DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management and environmental-asset monetization firm, today announced that it has signed a term sheet (the “Term Sheet ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

The draw for the FIFA World Cup 2026™ Play-Off Tournament, in which six teams will fight it out for two places at next year's global finals, has taken place at the Home of FIFA in Zurich. The Play-Off ...

OWENS CROSS ROAD, Ala. (WHNT) — The Owens Cross Roads City Council has voted to pursue legal action against a mental health facility operating in the city. During a special-called meeting on Thursday, ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

Senate Majority Leader John Thune (R-S.D.) is set to hold a vote Friday with an eye toward ending the government shutdown. The GOP leader told lawmakers over a conference lunch that he will hold ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...

Scientists have uncovered a hidden weakness in one of the deadliest childhood cancers. The tumors, which spread quickly and are notoriously hard to treat, rely on a sugar-processing pathway to survive ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...